Similares a Phase 3b ENCORE: ALIS Improves MAC Lung Disease Outcomes | ATS 2026

20 vecinos (text_768) · 117 views · HCPLive · Estados Unidos


★	Phase 3b ENCORE: ALIS Improves MAC Lung Disease Outcomes \| ATS 2026	HCPLive @hcplivenews	117	Estados Unidos
9	Mepolizumab Add-On Reduces COPD Exacerbations in Triple-Therapy Patients \| ATS 2026	HCPLive @hcplivenews	1.2K	Estados Unidos	84
1	88% Culture Conversion in MAC Lung Disease—Is Earlier ALIS the Answer? \| #ats2026	HCPLive @hcplivenews	909	Estados Unidos	93
19	Treatment of NTM	National Jewish Health @nationaljewishhealth	771	Estados Unidos	84
8	Efdoralprin Alfa Normalizes Alpha-1 Antitrypsin Levels I #ats2026	HCPLive @hcplivenews	548	Estados Unidos	84
20	La Universitat se suma al Dia Europeu de Dèficit d'Alfa-1	Universitat de València @universitatvalencia	481	España	83
7	Inhaled Treprostinil for IPF: TETON-1 Phase 3 Results With Steven Nathan, MD \| ATS 2026	HCPLive @hcplivenews	301	Estados Unidos	85
17	Treatment of systemic sclerosis-associated interstitial lung disease: where do we stand in 2025?	ERN ReCONNET @ernreconnet	285	—	84
14	Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD	HCPLive @hcplivenews	198	Estados Unidos	84
5	Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results	HCPLive @hcplivenews	156	Estados Unidos	86
16	Mepolizumab Reduced COPD Hospitalizations in Eosinophilic Disease \| ATS 2026 With Gerard Criner, MD	HCPLive @hcplivenews	113	Estados Unidos	84
13	Sotatercept May Improve RV Function in Group 3 3 Pulmonary Hypertension	HCPLive @hcplivenews	112	Estados Unidos	84
3	AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD	HCPLive @hcplivenews	105	Estados Unidos	86
4	Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results	HCPLive @hcplivenews	82	Estados Unidos	86
18	Dupilumab Doubled Asthma Remission Odds in Type 2 Asthma:	HCPLive @hcplivenews	71	Estados Unidos	84
12	ATS 2026 Asthma Updates: Tezepelumab, Dupilumab, OCS Reduction & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	70	Estados Unidos	84
2	ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	55	Estados Unidos	88
11	SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026	HCPLive @hcplivenews	48	Estados Unidos	84
10	Pegtarazimod Cuts Oxygen Need in Hospitalized COPD Patients \| ATS 2026 \| Gerald Criner, MD	HCPLive @hcplivenews	29	Estados Unidos	84
6	Emerging Data in NTM Lung Disease: Potential Impacts and Ongoing Challenges	ReachMD @reachmd	7	Estados Unidos	86
15	Early Recognition and Diagnostic Confidence in NTM Lung Disease	ReachMD @reachmd	6	Estados Unidos	84